Clinical Specialty Index

New obesity guidelines emphasize early screening and tailored diagnosis.

Atrial appendage closure reduces bleeding in atrial fibrillation.

Four-year study shows lasting ulcerative colitis remission with mirikizumab.

This retrospective, propensity-matched comparison informs adjuvant regimen selection for resected high-risk hepatocellular carcinoma, weighing locoregional chemoembolization against a targeted-immunotherapy combination.

Balance risks: Antithrombotic therapy post-bypass under scrutiny.

Semaglutide reduces alcohol intake in comorbid obesity.

Could a new anticoagulant improve stroke prevention?

2026 sepsis guidelines enhance antimicrobial and fluid strategies.

Obinutuzumab improves SLE outcomes in the recent ALLEGORY trial.

New biomarkers offer promise for early detection of chemotherapy-induced heart damage.

The ADA's new Obesity Association guideline reframes obesity pharmacotherapy around treating obesity-related diseases rather than weight targets alone, elevates GLP-1RA and dual GIP/GLP-1RA agents to preferred status across multiple comorbidities, and mandates indefinite continuation to prevent weight recurrence.

FIND-CKD extends the kidney-protective role of finerenone from diabetic to non-diabetic chronic kidney disease, giving pharmacists a new evidence-based add-on to renin-angiotensin system blockade.

TIGRIS trial indicates improved outcomes for patients with specific endotoxin activity in septic shock.

Introduces expanded diabetes screening and diagnostic recommendations across diverse populations for pharmacy practice.

GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.